Figure 6 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Year: 2026
Type: other
Abstract: In vivo response of FaDu parental and FaduAfaR xenografts to VIC-1911 + adavosertib drug combination. A, Mice harboring either FaDu parental or FaDuAfaR xenograft tumors were daily treated with vehicle (n = 8 for parental, n = 5 for AfaR) or VIC-1911 60 mg/kg (n = 8 for parental, n = 5 for AfaR) for 12 days to compare response to monotherapy. B and C, Mice harboring FaDu parental (B) or FaduAfaR (C) xenografts were daily treated with vehicle (n = 7), adavosertib 120 mg/kg (n = 7), VIC-1911 30 mg/kg (n = 8), or combination (n = 8) for 21 days. P values are based on two-way ANOVA followed by the Tukey multiple comparison test. D and E, Representative IHC staining images (D) and quantification (E) of Ki-67 and cleaved caspase 3 in FaDu parental or FaDuAfaR xenograft tumors treated with the indicated drugs. Mice harboring FaDu parental or FaDuAfaR xenografts were daily treated with vehicle (n = 7), adavosertib 120 mg/kg (n = 7), VIC-1911 30 mg/kg (n = 8), or combination (n = 8) for 21 days. Scale bars, 300 μm. Violin plots display median (-) and quartiles (…). P values are based on two-way ANOVA followed by the Tukey multiple comparison test. Only significant comparisons are displayed in the violin plots. P = 0.0332; **, P = 0.0021; ***, P = 0.0002; ****, P ≤ 0.0001.
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7202360127
Cites:
Cited by:
Related to: